BLOG / 🇺🇸 United States / broad market · · monthly

US Pre-Market SEC Filings Roundup — November 03, 2026

USA Before-Market Intelligence

By Gunpowder Editorial ·

28 high priority 14 medium priority 42 total filings analysed

Executive Summary

Overnight SEC filings for 2026-11-02 to 2026-11-03 show a sharply bifurcated landscape: strong top-line and earnings momentum at Palantir (revenue +95.9% YoY to $2.31B), Paymentus (+19.8% revenue), Douglas Dynamics (+35% net sales), Leidos (EPS guidance raised a third straight quarter) and CorVel (+11% revenue, +24% EPS), offset by widespread weakness in cash generation, impairments and balance-sheet stress.

Several filings point to distressed or restructuring situations, including Karyopharm's prepackaged Chapter 11 (voting deadline November 30, 2026), Mercer International's prepackaged Chapter 11 recapitalization with existing common equity cancelled, and going-concern-type disclosures at Fusemachines, InMed, Crown Equity and Limitless Projects. Within REITs and credit, Realty Income's revenue rose 10.3% YoY but impairments (+48.1%) and credit loss provisions (more than doubled) rose faster, while Nuveen Churchill's NAV per share fell to $17.13 and nine-month net increase in net assets dropped 43.1%. Energy and commodity-linked names showed mixed results: Archrock's revenue fell 3.0% and adjusted free cash flow dropped 56.4% despite reaffirmed EBITDA guidance, and Black Stone Minerals' net income fell from $106.4M to $52.4M QoQ on derivative losses even as its distribution rose. Insider activity was light and mostly routine (tax withholding, 10b5-1 sales/purchases), with the notable exception of ARCH Venture entities buying 1.2M Aspen Neuroscience shares at $15.00 (~$18M). The most actionable event is the Arkhouse/Cobblers Cove $39.00/share take-private proposal for Dine Brands, rejected by the Board on October 29 with the investors signaling renewed interest on November 2.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Schedule 13D · Form 4 · 425 · 10-Q · 8-K · 10-K

Tracking the trend? Catch up on the prior US Pre-Market SEC Filings Roundup digest from November 02, 2026.

Investment Signals (12)

  • Q3 2026 revenue $2.31B (+95.9% YoY), operating income nearly tripled to $1.08B (46.9% margin), accumulated deficit reduced to $502.0M from $3.56B at year-end 2025

  • Net sales +35% YoY to $218.0M, net income +166% to $21.2M, Work Truck Attachments margin +945 bps to 24.8%; raised low end of FY26 guidance (Adj. EPS $3.00-3.40)

  • ▲

    Q3 FY26 revenue +4% YoY, non-GAAP EPS +19% to $3.62; FY26 non-GAAP EPS guidance raised to $12.50-$12.70 for the third consecutive quarter, though revenue guidance cut to $18.00-$18.20B on the Altaris JV contribution

  • ▲

    Q2 FY2027 revenue +11% to $267M, gross profit +24%, diluted EPS +24% to $0.67; $270M cash with no borrowings and $18.1M of buybacks

  • Q3 revenue +19.8% to $372.2M, nine-month revenue +26.0%, net income +54.9%; however cash taxes more than doubled to $30.6M, limiting operating cash flow growth to 5.1%

  • ARCH Venture Partners XIV and ARCH Venture Fund X each bought 1,200,000 common shares at $15.00 (~$18M each) as 10% owners, alongside director and executive-chair conversions

  • Arkhouse/Cobblers Cove $39.00/share cash take-private proposal rejected by the Board Oct 29; investors on Nov 2 reiterated interest in a transaction, implying a potential premium catalyst

  • Q3 revenue -52.4% YoY to $110.0M and net loss of $32.7M, but operating cash flow improved to $122.4M for nine months and debt reduced to $507.7M from $572.1M

  • Archrock ↓ (BEARISH)
    ▲

    Q3 revenue -3.0% YoY to $370.8M, adjusted free cash flow -56.4% to $49.6M and after-dividend FCF -88.2% to $9.0M, though leverage cut to 2.5x and FY26 EBITDA guidance ($865-885M) reaffirmed

  • ▲

    Q3 revenue +10.3% YoY to $1.62B, but impairments +48.1% to $111.6M and nine-month credit loss provisions more than doubled to $60.6M

  • Q3 total investment income -14.5% YoY to $43.7M; nine-month net increase in net assets from operations -43.1% to $28.3M; NAV per share down to $17.13 from $17.72

  • ▲

    Q3 revenue +3.0% but operating expenses +57.7%, net loss widened to $4.6M from $1.2M, cash fell to $1.45M from $4.22M at year-end 2025

Risk Flags (10)

  • Joint prepackaged Chapter 11 filed in S.D. Texas; plan supported by 100% of 1L term loan, notes and preferred holders, ballot deadline November 30, 2026, with confirmation not assured

  • Prepackaged Chapter 11 on $1.275B senior notes; existing common stock cancelled, holders receive only ~8.5% of new common and 3.5% of new convertible preferred, Nasdaq delisting expected

  • Nine-month 2026 net loss of $206.1M versus $107.2M net income a year earlier, driven by a $191.3M long-lived asset impairment; Q3 SG&A rose 19.5% despite revenue falling 52%

  • Operating cash flow swung to $(27.1)M for nine months from +$12.5M, and cash fell to $7.7M, despite narrower net loss

  • Net loss widened 35% to $2.33M, total shareholders' equity turned negative at $(1.2)M, cash down to $1.09M, with pending Mentari merger and BayMedica wind-down

  • Q3 net income fell to $52.4M from $106.4M QoQ on $30.2M commodity derivative losses; working-interest production down 31% YoY to 1.1 MBoe/d

  • Nine-month G&A +15.1% to $170.8M and credit loss provisions +90% to $60.6M signal deteriorating loan and preferred equity book quality

  • Revenue fell 63% YoY to $102, stockholders' deficit deepened to $(407.8)K, cash $1,137 against $417.5K of liabilities, funded by related-party borrowing

  • ▼

    OSB segment Adjusted EBITDA $(24)M in Q3, net sales down 24% YTD to $530M, FY26 OSB EBITDA guided to $(95)M, while crude-driven raw material costs weigh on Siding

  • Credit facility amended with 9.99% beneficial ownership limit for lender including Dr. Manmohan Patel and replacement of the no-short-selling covenant; $7.4M drawn of $36M facility

Opportunities (8)

  • $39.00/share proposal from Arkhouse/Cobblers Cove with Board rejection and investor re-engagement signal; activist holds ~4.3% and may escalate or raise bid

  • Operating margin 46.9% and deferred revenue up to $661.3M from $409.0M, with customer deposits rising to $512.6M, indicating forward revenue visibility

  • Year-to-date parts and accessories shipments already exceed the full-year 2025 record; pre-season split shifted to ~50/50 versus 60/40 in 2025

  • ◆

    Third consecutive EPS guidance enhancement with Adjusted EBITDA margin up to 13.9%; SES JV contribution to Altaris simplifies the portfolio

  • Leverage reduced to 2.5x from 3.1x, dividend raised ~10% YoY, FY26 EBITDA guidance $865-885M reaffirmed; sale of ~112,000 non-strategic horsepower supports deleveraging

  • Development agreement expanded by 730,000 gross acres to 950,000 total, distribution raised 17% since Q1 2026 to $0.35 with 1.25x coverage

  • Eliminates ~$96M of annual cash interest and ~$1.1B of notes, with no maturities until 2031 and $400M new money; plan confirmation targeted within ~45 days

  • ◆

    $270M cash with no borrowings and $18.1M repurchased in the quarter, with diluted EPS up 24%

Sector Themes (6)

  • Restructuring and Recapitalization Wave
    ◆

    Karyopharm (prepackaged Chapter 11), Mercer International (prepackaged Chapter 11), and InMed's pending merger signal distressed capital structures being resolved through equity-dilutive or wipe-out restructurings in biotech and industrials [implication: senior creditors dominate outcomes; common equity often cancelled]

  • Credit and Impairment Pressure in Private Lending and Net-Lease REITs
    ◆

    Nuveen Churchill NAV down, investment income -14.5% YoY; Realty Income impairments +48.1% and credit losses more than doubled; points to rising stress in private credit and real-estate loan books [implication: watch NAV marks and provisions across BDC and REIT peers]

  • Biotech Going-Concern Cluster
    ◆

    Enzon, InMed, Emergent and Fusemachines show revenue declines, negative operating cash flow, impairment charges and liquidity runway concerns; combined with Karyopharm and Mercer, 5 of ~8 biotech/life-sciences filings carry distress signals [implication: financing or restructuring likely for sub-scale names]

  • Cash Conversion Divergence Despite Earnings Growth
    ◆

    Paymentus, Archrock and Black Stone show earnings or EBITDA growth but weaker cash flow (cash taxes doubled at Paymentus, adjusted FCF -56% at Archrock, derivative losses at Black Stone); quality-of-earnings scrutiny warranted [implication: prioritize FCF over accounting profit in screens]

  • Industrial Demand Mix Shifts
    ◆

    Douglas Dynamics' Work Truck Attachments +78% contrasts with Work Truck Solutions +3%; Louisiana-Pacific Siding +7% vs OSB -24% YTD; Emergent product sales -52%; demand is diverging by sub-segment rather than moving uniformly [implication: segment-level analysis needed]

  • Insider Activity Largely Routine, Venture Conviction Notable
    ◆

    Most insider filings are tax withholding or 10b5-1 transactions with limited signal; the exception is ARCH Venture buying ~$36M across two entities in Aspen Neuroscience at $15.00, indicating institutional conviction ahead of a potential liquidity event [implication: monitor for follow-on financing or listing]

Watch List (9)

  • Prepackaged Chapter 11 voting deadline 4:00 p.m. CT on November 30, 2026; confirmation and conditions precedent still uncertain

  • Arkhouse/Cobblers Cove response to Board rejection; any revised bid above $39.00 or proxy/tender action following November 2 letter

  • Plan confirmation expected within ~45 days of filing (around mid-December 2026); recapitalization targeted for completion by end of 2026

  • Post-SES/Altaris integration and FY26 close; revenue guidance now $18.00-$18.20B; watch Q4 managed health and federal civilian IT trends

  • Q4 winter-weather variability flagged; monitor Work Truck Solutions margin recovery from 8.1% and guidance band $770-805M sales

  • Caturus pilot well timing (first additional area well by Q1 2028); distribution payable November 13, 2026 to holders of record November 6

  • Credit loss and impairment trajectory in Q4 and NAV per share revaluation; debt reduction at Nuveen Churchill ($1.028B vs $1.115B)

  • ARCH Venture's $15.00 entry price and any subsequent financing or listing timetable

  • Form F-4 effectiveness and shareholder votes needed for the $250M valuation SPAC combination

Filing Analyses (42)
Dine Brands Global, Inc. SC 13D mixed materiality 8/10

02-11-2026

Arkhouse Management Co. LP and affiliates (with Gavriel Kahane) filed a Schedule 13D disclosing beneficial ownership of 546,700 shares of Dine Brands Global (~4.3% of the 12,659,150 shares outstanding as of July 26, 2026), acquired for approximately $15,683,250. On October 26, 2026, Arkhouse and Cobblers Cove delivered a non-binding proposal to acquire all outstanding shares for $39.00 per share in cash, which the Dine Brands Board rejected on October 29, 2026; the investors responded on November 2, 2026 expressing disappointment at the rejection without engagement and reiterating interest in a transaction. The filing signals activist pressure for a potential take-private, though the Board's swift rejection and the non-binding nature of the proposal leave the outcome uncertain.

  • · Board rejected the $39.00/share proposal via letter dated October 29, 2026, three days after it was delivered
  • · Reporting Persons may acquire additional shares, dispose of holdings, enter hedges, or abandon the acquisition intention
  • · Shares were acquired in open market purchases using working capital, potentially including margin borrowing with shares pledgeable as collateral
  • · Cobblers Reporting Persons are filing a separate Schedule 13D on the same issuer
  • · Issuer formerly named DineEquity, Inc. (changed 2008) and IHOP Corp (changed 1994)
Dolphin Entertainment, Inc. 4 positive materiality 3/10

02-11-2026

Chief Executive Officer O'Dowd William IV bought 5,000 Common Stock at $0.99 (~$4.97K). O'Dowd William IV holds 588,442 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

  • · Chief Executive Officer O'Dowd William IV bought 5,000 Common Stock at $0.99 (~$4.97K)
VAIL RESORTS INC 4 neutral materiality 5/10

02-11-2026

GC & Chief Public Affairs Ofc DeCecco Julie A. had withheld for taxes 31 Common Stock at $151.83 (~$4.71K). DeCecco Julie A. holds 3,470 shares after the transaction.

  • · GC & Chief Public Affairs Ofc DeCecco Julie A. exercised/converted 106 Common Stock
  • · GC & Chief Public Affairs Ofc DeCecco Julie A. had withheld for taxes 31 Common Stock at $151.83 (~$4.71K)
  • · GC & Chief Public Affairs Ofc DeCecco Julie A. exercised/converted 106 Restricted Share Unit
Aspen Neuroscience, Inc. 4 neutral materiality 5/10

02-11-2026

Director Spaventa Andrew exercised/converted 70,194 Common Stock. 4 transactions reported in total. Spaventa Andrew holds 180,221 shares after the transaction.

  • · Director Spaventa Andrew exercised/converted 70,194 Common Stock
  • · Director Spaventa Andrew exercised/converted 180,221 Common Stock
  • · Director Spaventa Andrew exercised/converted 70,194 Series Seed Convertible Preferred Stock
  • · Director Spaventa Andrew exercised/converted 180,221 Series C Convertible Preferred Stock
Aspen Neuroscience, Inc. 4 neutral materiality 5/10

02-11-2026

Executive Chair Hasnain Faheem exercised/converted 14,913 Common Stock. 6 transactions reported in total. Hasnain Faheem holds 7,120 shares after the transaction.

  • · Executive Chair Hasnain Faheem exercised/converted 14,913 Common Stock
  • · Executive Chair Hasnain Faheem exercised/converted 14,316 Common Stock
  • · Executive Chair Hasnain Faheem exercised/converted 7,120 Common Stock
  • · Executive Chair Hasnain Faheem exercised/converted 14,913 Series A-1 Convertible Preferred Stock
  • · Executive Chair Hasnain Faheem exercised/converted 14,316 Series A-2 Convertible Preferred Stock
  • · Executive Chair Hasnain Faheem exercised/converted 7,120 Series C Convertible Preferred Stock
SONOCO PRODUCTS CO 4 neutral materiality 2/10

02-11-2026

Pres. Consumer Pkg Americas Haynes Ernest D III had withheld for taxes 60 Restricted Stock Units at $49.96 (~$3K).

  • · Pres. Consumer Pkg Americas Haynes Ernest D III had withheld for taxes 9 Dividend Equivalents on Restricted Stock Units at $49.96 (~$450)
  • · Pres. Consumer Pkg Americas Haynes Ernest D III had withheld for taxes 60 Restricted Stock Units at $49.96 (~$3K)
Aspen Neuroscience, Inc. 4 positive materiality 5/10

02-11-2026

10% owner ARCH Venture Partners XIV, L.P. bought 1,200,000 Common Stock at $15.00 (~$18M). ARCH Venture Partners XIV, L.P. holds 1,200,000 shares after the transaction.

  • · 10% owner ARCH Venture Partners XIV, L.P. bought 1,200,000 Common Stock at $15.00 (~$18M)
Aspen Neuroscience, Inc. 4 positive materiality 6/10

02-11-2026

10% owner ARCH Venture Fund X, L.P. bought 1,200,000 Common Stock at $15.00 (~$18M). 21 transactions reported in total. ARCH Venture Fund X, L.P. holds 1,200,000 shares after the transaction.

  • · 10% owner ARCH Venture Fund X, L.P. bought 66,666 Common Stock at $15.00 (~$1M)
  • · 10% owner ARCH Venture Fund X, L.P. exercised/converted 187,182 Common Stock
  • · 10% owner ARCH Venture Fund X, L.P. exercised/converted 298,258 Common Stock
  • · 10% owner ARCH Venture Fund X, L.P. exercised/converted 286,304 Common Stock
  • · 10% owner ARCH Venture Fund X, L.P. exercised/converted 295,490 Common Stock
  • · 10% owner ARCH Venture Fund X, L.P. exercised/converted 259,948 Common Stock
  • · 10% owner ARCH Venture Fund X, L.P. bought 66,667 Common Stock at $15.00 (~$1M)
  • · 10% owner ARCH Venture Fund X, L.P. exercised/converted 298,258 Common Stock
Inflection Point Acquisition Corp. VI 425 neutral materiality 4/10

30-10-2026

Inflection Point Acquisition Corp. VI (IPFX) filed a Form 425 disclosing a LinkedIn communication by Jim Bridenstine dated October 29, 2026, related to its proposed business combination with Quantum Space, LLC. The SEC declared the Form S-4 registration statement (File No. 333-299286) effective on October 28, 2026, and a definitive proxy statement/prospectus will be mailed to shareholders for a vote on the deal. The filing contains no financial figures or deal terms, and flags that Quantum Space's flagship Ranger vehicle is still in development and has not been manufactured, operated or sold to date.

  • · Form S-4 registration statement (File No. 333-299286) was declared effective by the SEC on October 28, 2026
  • · The communication was posted on Jim Bridenstine's LinkedIn account on October 29, 2026, and filed via Form 425 on October 30, 2026
  • · Quantum Space's Ranger vehicle is currently in development and has not been manufactured, operated or sold to date
  • · Ranger is designed with a refuelable and modular architecture and an intended operational life of up to 15 years
  • · Inflection Point's address is 1680 Michigan Avenue, Suite 700 #1031, Miami Beach, FL 33139; proxy solicitor Alliance Advisors can be reached at 1-855-206-2037
  • · Risk factors include shareholder redemption levels, failure to obtain shareholder approval or financing, and delays or failures in satellite launches
Palantir Technologies Inc. 10-Q positive materiality 9/10

03-11-2026

Palantir reported Q3 2026 revenue of $2.31B, up 95.9% YoY from $1.18B, with net income attributable to common stockholders of $1.13B versus $475.6M a year earlier and diluted EPS of $0.44 vs $0.18. Operating income nearly tripled to $1.08B (46.9% margin) from $393.3M, while gross profit rose 98.2% to $1.93B. However, operating expenses grew faster than gross profit in some lines — sales and marketing jumped 44.5% and R&D rose 52.4% — and other income swung to a $25.8M expense from a $27.5M gain, tempering the otherwise strong quarter.

  • · Accumulated deficit shrank to $502.0M from $3.56B at December 31, 2025, reflecting sustained profitability.
  • · Total stockholders' equity rose to $11.23B from $7.39B at year-end 2025.
  • · Deferred revenue (current) grew to $661.3M from $409.0M, and customer deposits (current) rose to $512.6M from $357.1M.
  • · Accounts receivable increased to $1.88B from $1.04B, and nine-month receivables use of cash widened to $843.4M from $423.0M.
  • · Nine-month 2026 stock-based compensation was $786.5M, up from $488.6M a year earlier.
  • · Other comprehensive income swung to a $12.4M loss from $13.9M income at year-end 2025, driven by a $22.7M unrealized loss on available-for-sale securities.
  • · Nine-month 2026 net cash used in investing activities was $1.14B versus $1.83B in 2025.
  • · Cash, cash equivalents, and restricted cash ended the period at $3.65B versus $1.64B a year earlier.
Karyopharm Therapeutics Inc. 8-K negative materiality 9/10

03-11-2026

Karyopharm Therapeutics Inc. and affiliate KPT Texas LLC filed a joint prepackaged Chapter 11 case in the U.S. Bankruptcy Court for the Southern District of Texas (Houston Division), Case No. 26-_____, with joint administration requested. The Prepackaged Plan is supported by Consenting Stakeholders holding 100% of the 1L Term Loan Claims, 1.5L 2028 Notes Claims, 2L 2029 Notes Claims, RIFA Claims, and Existing Preferred Interests, with voting classes 3-6 and a ballot deadline of 4:00 p.m. Central Time on November 30, 2026. General Unsecured Claims are unimpaired and to be paid in full, and the Debtors intend to operate in the ordinary course and pay trade creditors, customers, and employees in full, though confirmation and effectiveness remain subject to Bankruptcy Court approval and conditions precedent with no assurance of completion.

  • · Case filed in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division, Case No. 26-_____ (joint administration requested)
  • · Voting deadline: 4:00 p.m. prevailing Central Time on November 30, 2026; ballots to be received by claims and balloting agent Stretto, Inc.
  • · Claims and balloting agent contact: (866) 270-4922 toll-free in U.S./Canada or +1 (949) 561-0471 international
  • · Existing Preferred Interests were issued on September 17, 2026 as consideration under the September Forbearance Agreement
  • · Debtors' service address: 85 Wells Avenue, Suite 210, Newton, Massachusetts 02459
  • · Solicitation was commenced pre-petition under section 4(a)(2) of the Securities Act and Regulation S, limited to Eligible Holders (QIBs, accredited investors, or non-U.S. persons)
  • · Post-petition issuance of Reorganized Parent Common Stock, New Common Stock, and MF CVRs to rely on section 1145(a) of the Bankruptcy Code; New Common Stock issued to Ayrmid equityholders as Merger Consideration and Omisirge Contingent Equity to rely on section 4(a)(2)/Regulation S
  • · Certain exhibit portions omitted pursuant to Item 601 of Regulation S-K and marked [***]
  • · Disclosure Statement has not been approved by the Bankruptcy Court; confirmation and effectiveness subject to conditions precedent in Article IX of the Prepackaged Plan
MERCER INTERNATIONAL INC. 8-K mixed materiality 9/10

03-11-2026

Mercer International entered restructuring support agreements with holders of more than 87% of its Senior Notes and a majority of its common shareholders to implement a prepackaged Chapter 11 recapitalization addressing $1.275 billion of Senior Notes. The deal exchanges approximately $1.1 billion of notes (about 88% of Senior Note debt) for equity, eliminates roughly $96 million of annual cash interest, and raises $400 million of new money via a fully backstopped rights offering of $420 million principal of new senior secured notes. However, existing common stock will be cancelled and holders receive only about 8.5% of new common stock and 3.5% of new convertible preferred, with Nasdaq delisting expected and no bond maturities until 2031.

  • · New notes mature four years and 364 days after issuance with no scheduled amortization; interest may be paid substantially in kind for the first two years
  • · No bond maturities until 2031
  • · Plan confirmation expected within approximately 45 days of filing; recapitalization targeted for completion by end of 2026
  • · Chapter 11 cases to be filed in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division
  • · Trade and other general unsecured claims are unimpaired and to be paid in full
  • · Mercer elected not to make the October 1, 2026 interest payment on its 12.875% Senior Notes due 2028 and on October 30, 2026 extended the grace period from 30 to 90 calendar days via supplemental indenture
  • · Mercer expects Nasdaq to notify it of a determination to delist the common stock; shares may trade over-the-counter
  • · Company intends to apply to list new common stock on Nasdaq or another national securities exchange after the effective date
  • · Existing credit facilities expected to be repaid in whole or in part and replaced with up to $300 million of new revolving commitments
NEWS CORP 8-K neutral materiality 2/10

03-11-2026

News Corporation filed an 8-K on November 3, 2026 disclosing routine daily ASX notifications (Exhibits 99.1 and 99.2) related to its existing stock repurchase program, under which it is authorized to acquire up to $1 billion in aggregate of Class A and Class B common stock. The filing contains no new repurchase authorization, no transaction amounts, and no financial results — it is a procedural disclosure of information already provided to the Australian Securities Exchange.

  • · Exhibits 99.1 and 99.2 are copies of information provided to the ASX on the dates noted therein; no specific transaction volumes or prices are disclosed in the filing text
  • · The repurchase program authorization of up to $1 billion was previously reported and is not newly established by this filing
  • · Company is required under ASX rules to disclose repurchase transactions on a daily basis, if any
  • · Filing includes standard forward-looking statement disclaimers regarding intent to repurchase shares from time to time
  • · Signed by Michael L. Bunder, Senior Vice President, Deputy General Counsel and Corporate Secretary, dated November 3, 2026
SmartStop Self Storage REIT, Inc. 8-K neutral materiality 2/10

03-11-2026

SmartStop Self Storage REIT declared a monthly common stock dividend of $0.13150685 per share for November 2026, payable December 15, 2026 to holders of record as of November 30, 2026. The declaration reflects a targeted annualized dividend of $1.60 per share. The filing contains no operating or financial performance data, so no period-over-period comparisons are available.

  • · Record date for the November 2026 dividend is November 30, 2026; payment date is December 15, 2026
  • · Dividend was declared by the Board of Directors on November 2, 2026
  • · Company is incorporated in Maryland, IRS Employer Identification No. 46-1722812, Commission File Number 001-42584
  • · Principal executive offices located at 10 Terrace Road, Ladera Ranch, California 92694
  • · Company is not an emerging growth company
Archrock, Inc. 8-K mixed materiality 7/10

03-11-2026

Archrock reported Q3 2026 revenue of $370.8 million, down 3.0% YoY from $382.4 million, as aftermarket services revenue fell 29.4% to $39.7 million on reduced major maintenance demand and lower parts sales. Net income rose 18.6% YoY to $84.5 million (EPS $0.48 vs $0.40) and Adjusted EBITDA grew 3.4% to $228.4 million, while contract operations revenue edged up 1.5% to $331.2 million but adjusted gross margin percentage slipped to 72% from 73%. The company declared a $0.23 quarterly dividend (~10% higher YoY), cut leverage to 2.5x from 3.1x, and reaffirmed full-year 2026 Adjusted EBITDA guidance of $865-$885 million.

  • · Total operating horsepower fell to 4.5 million from 4.7 million YoY, reflecting the sale of approximately 112,000 non-strategic operating horsepower.
  • · Spot horsepower utilization declined to 94.3% from 96.0% YoY.
  • · Adjusted free cash flow dropped 56.4% YoY to $49.6 million, and adjusted free cash flow after dividend fell 88.2% YoY to $9.0 million.
  • · No shares were repurchased during Q3 2026; $113.2 million remained available under the repurchase program.
  • · Since April 2023 program inception through September 30, 2026, 4,632,263 shares were repurchased for $96.9 million at an average price of $20.91 per share.
  • · Q3 2025 results included a $9.9 million net benefit from sales and use tax audit settlements; excluding it, Q3 2025 adjusted gross margin was $229.7 million (70%).
  • · Selling, general and administrative expense fell to $26.0 million in Q3 2026 from $37.7 million in Q3 2025.
  • · Net cash provided by operating activities was $158.8 million vs $164.5 million YoY.
  • · Dividend of $0.23 per share ($0.92 annualized) payable November 10, 2026 to holders of record November 3, 2026.
  • · Management cited customer maintenance deferrals and higher lube oil prices as near-term headwinds, offset by cost discipline.
  • · Strongest bookings quarter since Q2 2023, with strong Permian Basin bookings.
Aimei Health Technology Co., Ltd. 8-K/A neutral materiality 3/10

03-11-2026

Aimei Health Technology Co., Ltd. issued a $34,330.96 promissory note dated October 5, 2026 to affiliate Aimei Investment Ltd, disclosed via 8-K/A under Item 2.03. The note carries no interest, is payable at the closing of a business combination, and is convertible into private units at $10.00 per unit (each unit comprising one ordinary share plus one-fifth of a right). The Payee waives all claims against the IPO trust account, so repayment depends on completing a Business Combination or other non-trust funds.

  • · Note dated October 5, 2026; filing date November 3, 2026 (8-K/A).
  • · Maturity Date is the date the Maker consummates a Business Combination; principal may be prepaid without penalty.
  • · Conversion requires written notice at least two business days prior to closing of a Business Combination; no fractional units issued (cash paid instead).
  • · Events of Default include payment failure beyond 5 business days of Maturity, voluntary/involuntary bankruptcy (60-day unstayed order), breach of obligations, and unlawfulness.
  • · Payee waives all claims against IPO trust account funds; if no Business Combination, note repaid only from non-trust amounts.
  • · Governing law: New York; no personal liability for officers, directors, employees or stockholders.
CORVEL CORP 8-K positive materiality 7/10

03-11-2026

CorVel reported Q2 FY2027 revenue of $267 million, up 11% YoY from $240 million, with gross profit rising 24% to $72.3 million (27% margin) and diluted EPS up 24% to $0.67 from $0.54. Six-month revenue grew 11% to $527 million and EPS rose to $1.31 from $1.06. However, operating income growth of 28% was partly offset by a 19% increase in G&A to $26.5 million, and the company repurchased $18.1 million of stock while holding $270 million in cash with no borrowings.

  • · G&A expense rose 19% YoY to $26.5 million, outpacing revenue growth of 11%
  • · Gross margin held at 27% in Q2 FY2027
  • · Income tax provision increased to $11.8 million from $8.0 million YoY
  • · Basic weighted shares declined to 50.5 million from 51.3 million, reflecting buybacks
  • · Cash rose to $270.0 million from $233.1 million at March 31, 2026
  • · Treasury stock increased to $928.3 million from $887.7 million
  • · Retained earnings grew to $1,079.7 million from $1,013.4 million
  • · CERIS added a Top 10 national health plan and a Blue Cross Blue Shield market partnership
Midland States Bancorp, Inc. 8-K neutral materiality 3/10

03-11-2026

Midland States Bancorp declared a quarterly cash dividend of $0.33 per common share, payable November 20, 2026 to holders of record as of November 13, 2026. The Board also declared a $0.4844 per depositary share dividend on its 7.750% Series A preferred stock; however, the filing states an inconsistent payable date of September 30, 2026 against a record date of December 15, 2026, an apparent error in the source document.

  • · Common dividend record date: November 13, 2026; payable November 20, 2026
  • · Preferred dividend record date: December 15, 2026, with a stated payable date of September 30, 2026 (inconsistent/likely erroneous in source)
  • · Press release filed as Exhibit 99.1, dated November 2, 2026
  • · Company incorporated in Illinois, IRS EIN 37-1233196, Commission File Number 001-35272
  • · Principal executive offices: 1201 Network Centre Drive, Effingham, Illinois 62401
LOUISIANA-PACIFIC CORP 8-K mixed materiality 7/10

03-11-2026

LP Building Solutions reported Q3 2026 results with record Siding net sales up 7% YoY to $473 million and net income of $23 million (+$14 million YoY, $0.32 diluted EPS). However, Adjusted EBITDA was flat at $82 million, and the OSB segment remained weak with negative Adjusted EBITDA of $(24) million and a 24% YTD net sales decline to $530 million. Full-year 2026 guidance points to a ~1% Siding sales decline and consolidated Adjusted EBITDA of $270-280 million, with OSB Adjusted EBITDA guided to $(95) million.

  • · Adjusted Diluted EPS was $0.39, up $0.02 YoY; net income per diluted share was $0.32, up $0.20
  • · Siding Adjusted EBITDA improvement driven by $23M net price gains and $4M higher volumes, offset by $19M higher raw material/freight/labor costs, $6M maintenance costs, and $3M unfavorable inventory impacts
  • · Nine-month Siding Adjusted EBITDA fell $15M: net price +$77M, lower volumes -$55M, raw material/freight/labor costs +$35M (crude oil driven)
  • · Q3 OSB Adjusted EBITDA improved $3M on $14M lower inventory reserve adjustments and $1M lower SG&A, offset by $7M lower OSB prices and $7M higher inflationary costs
  • · Other operations net sales fell $3M (Q3) and $15M (9M); Adjusted EBITDA fell $4M and $24M respectively on South America weakness
  • · Full-year 2026 capex guidance ~$300M split between $140M strategic growth and $160M sustaining maintenance
  • · Other operations expected to contribute approximately $(15)M in Q4 and $(50)M full-year to consolidated Adjusted EBITDA
  • · OSB guidance assumes Random Lengths OSB prices unchanged from October 30, 2026
Allegiant Travel CO 8-K neutral materiality 5/10

03-11-2026

Allegiant Travel Company furnished an 8-K under Regulation FD disclosing unaudited pro forma financial information reflecting its May 13, 2026 acquisition of Sun Country Airlines Holdings, Inc., presented as if the deal closed January 1, 2025. The pro forma statements cover six quarterly periods (Q1 2025 through Q2 2026) and the full year 2025, attached as Exhibit 99.1. The filing contains no actual financial figures or performance metrics in the body text, so no period-over-period comparisons can be assessed from this document alone.

  • · Acquisition of Sun Country Airlines Holdings, Inc. completed May 13, 2026
  • · Pro forma information assumes the transaction closed January 1, 2025
  • · Pro forma periods: three months ended March 31, 2025; June 30, 2025; September 30, 2025; December 31, 2025; March 31, 2026; June 30, 2026; and year ended December 31, 2025
  • · Information furnished under Item 7.01 is not deemed 'filed' under Section 18 of the Exchange Act and not incorporated by reference
  • · Exhibit 99.1 contains the pro forma statements; no actual figures disclosed in the 8-K body
  • · Company incorporated in Nevada; principal offices at 1201 North Town Center Drive, Las Vegas, NV 89144
  • · Commission File Number 001-33166; IRS EIN 20-4745737
Bambusa Therapeutics, Inc. 8-K neutral materiality 4/10

03-11-2026

Bambusa Therapeutics, Inc. filed an 8-K disclosing an Amended and Restated Certificate of Incorporation adopted under Sections 242 and 245 of the Delaware General Corporation Law, approved by the Board and by written stockholder consent. The charter authorizes 1,200,000,000 total shares — 1,000,000,000 Common Stock and 200,000,000 Preferred Stock, each at $0.00001 par value — and introduces IPO-readiness governance provisions including a classified board, supermajority removal-for-cause, and elimination of stockholder written consent, all effective from the IPO Closing Time. No financial results, revenue, or period-over-period operating metrics were disclosed in this filing.

  • · Original Certificate of Incorporation was filed with the Delaware Secretary of State on March 14, 2024
  • · Registered office is 1209 Orange Street, Wilmington, DE 19801; registered agent is National Registered Agents, Inc.
  • · Charter adopted via Board action plus written stockholder consent under DGCL Section 228
  • · Directors may be removed only for cause and only by majority of voting power, once board is classified post-IPO
  • · Stockholder written consent eliminated and special meeting call rights restricted from and after IPO closing
  • · Board authorized to issue Preferred Stock in series with terms fixed by Board resolution
  • · Stockholders may not cumulate votes in director elections
  • · Director/officer liability eliminated to fullest extent permitted by DGCL, with indemnification provisions
DOUGLAS DYNAMICS, INC 8-K mixed materiality 8/10

03-11-2026

Douglas Dynamics reported record Q3 2026 results with net sales up 35% YoY to $218.0 million and net income up 166% to $21.2 million (EPS $0.89), driven by a 78% surge in Work Truck Attachments sales to $121.5 million. However, the Work Truck Solutions segment grew only 3% to $96.5 million while its Adjusted EBITDA fell to $7.8 million from $9.6 million and margin compressed 210 bps to 8.1% on inconsistent commercial demand. The company raised the lower end of its 2026 guidance (net sales $770-805M, Adjusted EPS $3.00-3.40) but flagged Q4 variability tied to winter weather timing and severity.

  • · Pre-season shipment split was approximately 50%/50% between Q2 and Q3 2026, versus 60%/40% in 2025
  • · Year-to-date parts and accessories shipments already exceeded the prior annual record set in 2025
  • · Work Truck Attachments Adjusted EBITDA margin rose 945 basis points to 24.8%
  • · Quarterly cash dividend of $0.295 per diluted share paid
  • · New Ohio facility expected to begin operations in the coming weeks
  • · 2026 capital expenditures expected at 2% to 3% of net sales
  • · Effective tax rate guidance held at 24%-25%
  • · 2026 outlook assumes average snowfall in Q4 2026
  • · Company surpassed full-year record Adjusted EPS achieved in 2019 through first nine months of 2026
  • · Earnings conference call scheduled November 3, 2026 at 10:00 a.m. Eastern Time
Curaleaf Holdings, Inc. 8-K neutral materiality 5/10

03-11-2026

Curaleaf Holdings, Inc. filed an 8-K on November 3, 2026 (event date November 2, 2026) disclosing via Regulation FD a press release announcing its acquisition of an equity interest in Boone Town Provisions. The filing contains no financial terms, purchase price, or ownership percentage for the transaction, and no financial statements were filed — only the press release (Exhibit 99.1) and cover page XBRL (Exhibit 104). The disclosure is signed by Chief Legal Officer Peter Clateman.

  • · No purchase price, equity stake percentage, or other deal terms were disclosed in the 8-K body
  • · No financial statements were filed under Item 9.01; only Exhibit 99.1 (press release dated November 2, 2026) and Exhibit 104 (Inline XBRL cover page)
  • · The information in Item 7.01 is furnished, not filed, and is not incorporated by reference into other filings
  • · Curaleaf is incorporated in British Columbia, Canada, with principal executive offices at 250 Harbor Drive, Third Floor, Stamford, Connecticut 06902
  • · Commission File Number 333-249081; I.R.S. Employer Identification Number 98-1461045
  • · No securities are registered under Section 12(b) of the Exchange Act
LIBERTY STAR URANIUM & METALS CORP. 8-K neutral materiality 3/10

03-11-2026

Liberty Star Uranium & Metals Corp. disclosed in an 8-K (Item 7.01, Regulation FD) that its Board unanimously extended all company-issued warrants expiring during 2026 by an additional three years, effective October 28, 2026. All other warrant terms remain unchanged, with the February 25, 2021 reverse split still applied equivalently to price and share count. The filing contains no financial results, revenue, or period-over-period metrics, and the disclosure is not deemed 'filed' under Section 18 of the Exchange Act.

  • · Warrants extended by an additional three years
  • · Extension applies to all warrants that expired or will expire during calendar year 2026
  • · Board action was unanimous, dated October 28, 2026
  • · Reverse split effective February 25, 2021 continues to apply equivalently to warrant price and share number
  • · 8-K signed November 2, 2026; filing date November 3, 2026
  • · Company incorporated in Nevada; principal offices in Tucson, AZ; IRS Employer ID 90-0175540; Commission File 000-50071
  • · Company is not an emerging growth company
Black Stone Minerals, L.P. 8-K mixed materiality 8/10

03-11-2026

Black Stone Minerals reported Q3 2026 net income of $52.4 million, down sharply from $106.4 million in Q2 2026 and $91.7 million in Q3 2025, largely due to a $30.2 million loss on commodity derivatives versus gains of $26.8 million and $27.3 million in the prior periods. Adjusted EBITDA rose to $104.1 million (+14% QoQ, +18% YoY) and distributable cash flow reached $93.0 million, while total production of 35.6 MBoe/d increased 6% QoQ but declined 2% YoY from 36.3 MBoe/d. The Board raised the quarterly distribution 9% QoQ and 17% since Q1 2026 to $0.35 per unit (1.25x coverage), and the Partnership expanded its Caturus development agreement by 730,000 gross acres to 950,000 total acres.

  • · Working-interest production fell to 1.1 MBoe/d in Q3 2026 from 1.6 MBoe/d in Q3 2025, a 31% YoY decline
  • · Distribution coverage of 1.25x; distribution payable November 13, 2026 to unitholders of record November 6, 2026
  • · Caturus expanded agreement: first additional area pilot well expected by Q1 2028, ramping to ~12 gross wells annually by 2034; second area pilot by end of 2031, ramping to ~12 gross wells annually by 2038; minimum annual commitments rise from 8,000 to 33,600 net lateral feet
  • · Revenant amendment increased 2027 drilling commitment by 7,000 gross lateral feet and extended second-AOI requirement to 2029
  • · Adamas: 7 gross (0.7 net) wells turned to sales in Q3 2026; 9 gross (0.9 net) of prior-year wells on sales, 4 gross (0.4 net) expected in Q4 2026
  • · Blue Arrow: 10 gross (0.9 net) of 25 gross wells turned to sales as of September 30, 2026
  • · Hedge position: oil swaps ~$64.39–$71.59/bbl through 4Q28; natural gas swaps ~$3.70–$3.84/MMbtu through 4Q28
  • · Next borrowing base redetermination scheduled April 2027; in compliance with all credit facility covenants
  • · Conference call November 3, 2026 at 9:00 a.m. Central Time
GLOBAL PAYMENTS INC 8-K neutral materiality 3/10

03-11-2026

Global Payments Inc. filed an 8-K disclosing amended and restated bylaws effective October 28, 2026, adding a new shareholder right to call special meetings (15% ownership threshold held continuously for one year) and codifying proxy access provisions. The bylaws also set procedural timelines (special meetings held 30-90 days after valid request) and exclusive jurisdiction/derivative ownership thresholds. No financial figures, earnings data, or monetary amounts were disclosed in this governance filing.

  • · Bylaws effective October 28, 2026, filed as Exhibit 3.1 on Form 8-K dated November 03, 2026
  • · Special meetings may be called by the Board, Chairman, CEO, or Secretary upon request of holders of at least 15% of voting power
  • · Requesting shareholders must have owned shares continuously for at least one year and maintain the threshold through the meeting date
  • · Board has discretion to cancel a Shareholder Requested Special Meeting under specified circumstances
  • · Bylaws include exclusive jurisdiction (Section 10.05) and ownership threshold for derivative proceedings (Section 10.06)
  • · Headquarters designated as Atlanta, Georgia; registered office and agent required in Georgia
  • · Emergency bylaws provisions included under Article XIII
Leidos Holdings, Inc. 8-K mixed materiality 8/10

03-11-2026

Leidos reported Q3 FY26 revenues of $4.63B, up 4% YoY, with net income of $413M (+12%) and non-GAAP diluted EPS of $3.62 (+19% YoY). Adjusted EBITDA rose 5% to $644M with margin of 13.9% (up from 13.8%), while revenue growth was partly offset by declines in some managed health and federal civilian IT programs. The company enhanced FY26 guidance for the third consecutive quarter, raising non-GAAP EPS to $12.50-$12.70 but lowering the revenue range to $18.00-$18.20B following the SES joint venture contribution to Altaris.

  • · Revenue growth was partly offset by declines in some managed health and federal civilian IT programs
  • · FY26 revenue guidance lowered to $18.00-$18.20B from prior $18.20-$18.40B following the SES joint venture contribution to Altaris (closed October 5, 2026)
  • · FY26 non-GAAP diluted EPS guidance raised to $12.50-$12.70 from $12.20-$12.50
  • · FY26 operating cash flow guidance raised to approximately $1.90B from approximately $1.85B
  • · Adjusted EBITDA margin guidance held at Mid 13%
  • · Q3 bookings of $5.5B with book-to-bill ratio of 1.2; trailing-twelve-month book-to-bill of 1.1
  • · Board declared quarterly dividend of $0.45 per share, payable December 31, 2026 to holders of record December 15, 2026
  • · GAAP and non-GAAP earnings benefited from a lower effective tax rate due to increased federal research tax credit and decreased unrecognized tax benefits
  • · Leidos has 50,000 global employees and reported approximately $17.2B annual revenues for fiscal year ended January 2, 2026
Tevogen Bio Holdings Inc. 8-K neutral materiality 5/10

03-11-2026

Tevogen Inc. (formerly Tevogen Bio Holdings Inc.) entered into a First Amendment to its Loan Agreement with The Patel Family, LLP on October 27, 2026, amending the original June 6, 2024 $36,000,000 credit facility. As of the First Amendment Effective Date, the unused portion of the Credit Commitment is $28,600,000, implying $7,400,000 has been drawn. The amendment also revised share-related provisions, including replacing a 'No Short Selling' covenant with 'Restrictions on Shares' and setting a 9.99% Beneficial Ownership Limitation for the lender and affiliates including Dr. Manmohan Patel.

  • · Amendment dated as of October 27, 2026; original Loan Agreement dated June 6, 2024
  • · Borrower renamed from Tevogen Bio Holdings Inc. to Tevogen Inc.
  • · Governing law is the State of New York; arbitration and jury trial waiver provisions incorporated
  • · Amendment effective upon execution and delivery by each party
  • · Commitment Shares, Purchase Option, and Issuance Cap provisions referenced in the conformed Loan Agreement
  • · Common Stock par value $0.0001 per share
Limitless Projects Inc. 10-K negative materiality 4/10

03-11-2026

Limitless Projects Inc. filed its FY2026 10-K showing zero revenue for both FY2026 and FY2025, with net loss widening 17.6% to $80,837 from $68,765. Total assets fell 27.5% to $101,187 while total liabilities rose 7.8% to $585,353, pushing stockholders' equity deeper negative to $(484,166) from $(403,329). The company holds zero cash and reported no operating, investing, or financing cash flows in FY2026, raising going-concern concerns.

  • · Company is incorporated in Wyoming but headquartered in Nairobi, Kenya (Westside Towers, Lower Kabete Road).
  • · Auditor is LAO Professionals (Firm ID 7057) located in Lagos, Nigeria.
  • · Entity classified as a non-accelerated filer, small business, and emerging growth company.
  • · Net loss attributable to Limitless was $46,943 in FY2026 vs $42,900 in FY2025; minority interest loss was $33,894 vs $25,865.
  • · Net loss per share was $(0.00) basic and diluted in both years on 100,608,200 weighted average shares.
  • · FY2025 equity statement shows a $153,093 adjustment to shareholders' fund (paid-in capital reduced $761,314, accumulated deficit improved $649,090).
  • · No cash paid for interest or income tax in either year.
  • · Accounts payable and accrued liabilities increased $42,423 in FY2026 vs a $35,434 decrease in FY2025.
  • · FY2025 cash flow shows $197,766 from software development investing activity and $(153,093) financing outflow; FY2026 shows no cash flows in any category.
Hartman vREIT XXI, Inc. 10-K mixed materiality 6/10

03-11-2026

Hartman vREIT XXI filed its 10-K annual report disclosing an 11-property portfolio totaling 899,667 square feet at 88% average occupancy, generating $11,909 thousand in annualized base rental revenue at an average base rent of $15.39 per occupied square foot. The portfolio is heavily concentrated in Houston office assets, with the Spectrum Building in San Antonio (73% occupancy) the weakest performer and Two Park Ten (100%) the strongest. The filing flags material refinancing risk, noting the need to refinance or extend indebtedness maturing after July 2027, including the largest credit facility in the portfolio, alongside elevated mortgage rates and office being viewed as an unfavorable asset class in debt markets.

  • · Average base rent per occupied square foot across portfolio is $15.39
  • · Highest base rent per occupied SF: Two Park Ten at $28.64; lowest: Willowbrook Building at $6.98
  • · Spectrum Building is the largest revenue contributor at $2,360 thousand despite only 73% occupancy
  • · Portfolio spans three property types: Retail (Village Pointe), Flex/R&D (Richardson Tech Center), and Office (9 properties)
  • · Houston accounts for 9 of 11 properties; San Antonio accounts for 2
  • · Debt maturing after July 2027 includes the largest credit facility in the portfolio and requires refinancing or extension
  • · Office is described as an unfavorable asset class in debt markets, making lender identification challenging
  • · Risk that inflation on gross-leased tenants is not captured in expense recoveries
  • · Failure to qualify as a REIT would subject the company to regular corporate income tax and eliminate distribution deductibility
Nuveen Churchill Direct Lending Corp. 10-Q negative materiality 7/10

03-11-2026

Nuveen Churchill Direct Lending Corp. reported Q3 2026 total investment income of $43.674M, down 14.5% YoY from $51.106M, with net investment income of $18.776M (down 12.2% YoY) and net increase in net assets from operations of $15.991M versus $18.658M a year earlier. For the nine months, total investment income fell 14.9% to $134.262M and net increase in net assets from operations dropped 43.1% to $28.272M, driven by a $18.564M net realized loss and $12.205M of unrealized depreciation. NAV per share declined to $17.13 from $17.72 at year-end 2025, while total investments at fair value fell to $1.862B from $1.962B and debt was reduced to $1.028B from $1.115B.

  • · Interest income from non-controlled/non-affiliate investments fell to $124.239M for nine months 2026 from $149.286M in 2025.
  • · Net expenses after incentive fees waived declined to $75.221M for nine months 2026 from $86.130M, partly due to a $2.253M incentive fee waiver in 2025 that did not recur.
  • · Interest and debt financing expenses decreased to $49.953M for nine months 2026 from $59.954M.
  • · Q3 2026 net realized loss was $4.014M versus a $1.521M gain in Q3 2025.
  • · Cash and cash equivalents and restricted cash ended at $39.113M versus $46.333M a year earlier.
  • · Net cash provided by operating activities was $110.897M for nine months 2026 versus $165.589M in 2025.
  • · No share repurchases occurred in nine months 2026 versus $65.746M in 2025.
  • · Total investments and cash equivalents were $1.897B, equal to 224.25% of net assets.
  • · Weighted average common shares outstanding were 49,387,065 for Q3 2026 versus 49,403,696 in Q3 2025.
Fusemachines Inc. 10-Q negative materiality 7/10

03-11-2026

Fusemachines reported Q3 2026 revenue of $1.845M, up 3.0% YoY from $1.792M, but gross profit slipped 1.5% to $0.981M as cost of revenue rose 8.5%. Operating expenses surged 57.7% YoY to $3.295M (driven by G&A up 62.6% and R&D up 73.3%), widening operating loss to $2.314M from $1.094M and net loss to $4.623M from $1.174M, exacerbated by a $2.212M loss on the forward purchase derivative liability. Nine-month revenue declined 4.5% to $5.518M while net loss widened to $8.344M from $5.213M, and cash fell to $1.454M from $4.221M at year-end 2025.

  • · Net loss per common share was $(0.15) in Q3 2026, flat versus $(0.15) in Q3 2025, despite the larger net loss, due to weighted-average shares rising to 30,586,609 from 7,672,654
  • · Nine-month net loss per share improved to $(0.29) from $(0.70) on higher share count
  • · Gain on extinguishment of payable of $612K in 9M 2026 and $105K in Q3 2026
  • · Interest expense rose to $353K in Q3 2026 from $74K in Q3 2025
  • · Forward purchase derivative liability fell to $708K at Sep 30, 2026 from $9,692K at Dec 31, 2025
  • · Company issued 2,138,935 common shares to settle $1,298K of outstanding vendor invoices and 530,902 shares to settle $460K of employee severance
  • · Accounts payable of $4.527M and accrued expenses of $4.734M exceed cash of $1.454M as of September 30, 2026
  • · Deemed dividend of $84K related to Shortfall Warrants modification in 9M 2026
  • · Convertible notes payable, current of $1,245K newly recorded at Sep 30, 2026
InMed Pharmaceuticals Inc. 10-Q negative materiality 7/10

03-11-2026

InMed Pharmaceuticals filed its 10-Q for the quarter ended September 30, 2026, reporting a net loss of $2,330,778 versus a $1,726,899 net loss in the prior-year quarter, a 35% widening of losses. Revenue was nil as the company operates without commercial sales, while total operating expenses rose 4.4% to $2,009,320 driven by a 45.6% jump in G&A to $1,804,625, partially offset by a 64.2% decline in R&D to $206,015. Cash and cash equivalents fell to $1,094,488 from $2,194,413 at June 30, 2026, and total shareholders' equity turned negative at $(1,199,396), raising going-concern concerns amid a pending merger with Mentari and wind-down of the BayMedica segment.

  • · Revenue was nil in both periods as the company has no commercial sales from continuing operations.
  • · Loss per share narrowed to $(0.42) from $(0.44) despite the larger net loss, due to a 38.3% increase in weighted average shares outstanding to 5,469,448 from 3,954,549.
  • · Discontinued operations swung to a $335,766 loss from a $103,449 income in the prior-year quarter.
  • · Total shareholders' equity turned negative at $(1,199,396) from $1,075,007 at June 30, 2026.
  • · Cash burn improved: operating cash use fell to $1,142,342 from $1,930,803 year-over-year.
  • · Property, equipment and ROU assets fell to zero from $221,037, and prepaids dropped to $99,682 from $241,296.
  • · 154,299 pre-funded warrants were exercised for $40,000 in proceeds during the quarter.
  • · The filing flags risks including failure to obtain shareholder approvals for the Merger, potential payment of a termination fee, possible dissolution and liquidation if the Merger is not completed, and material adverse impact from the BayMedica wind-down due to recent U.S. legislation.
ENZON PHARMACEUTICALS, INC. 10-Q mixed materiality 6/10

03-11-2026

Enzon Pharmaceuticals filed its Q3 2026 10-Q reporting net sales of $95,279 thousand for the three months ended September 30, 2026, up 4.5% YoY from $91,162 thousand, while nine-month net sales declined 3.8% to $271,947 thousand from $282,629 thousand. The company narrowed its quarterly net loss to $6,440 thousand from $12,996 thousand and its nine-month net loss to $18,295 thousand from $46,848 thousand, helped by lower impairment and restructuring charges. However, operating cash flow swung negative to $(27,066) thousand from $12,491 thousand, and cash and equivalents fell to $7,747 thousand from $9,217 thousand at year-end 2025.

  • · Q3 2026 SG&A fell to $11,189 thousand from $13,522 thousand YoY
  • · Nine-month 2026 asset impairment expense was $362 thousand versus $12,100 thousand in 2025
  • · Nine-month 2026 restructuring expense was $714 thousand versus $6,606 thousand in 2025
  • · Nine-month 2026 income tax provision was $1,081 thousand versus $14,890 thousand in 2025
  • · Receivables rose to $69,981 thousand from $60,182 thousand at Dec 31, 2025
  • · Inventories rose to $100,337 thousand from $96,755 thousand at Dec 31, 2025
  • · Basic and diluted EPS improved to $(0.45) in Q3 2026 from $(2.40) in Q3 2025
  • · Weighted average diluted shares rose to 14,331,620 from 5,419,340 in Q3 YoY
  • · On March 25, 2026, 5,658,396 Enzon common shares were issued to IEH Parties in respect of 39,277 Series C Preferred shares
  • · 384 Series C Preferred shares remained outstanding post-closing, carried at $433 thousand mezzanine equity
  • · Retained earnings deficit widened to $(30,035) thousand from $(11,881) thousand at Dec 31, 2025
TACTILE SYSTEMS TECHNOLOGY INC 10-Q/A neutral materiality 1/10

03-11-2026

Tactile Systems Technology filed a 10-Q/A amendment on November 03, 2026, providing only cover-page registrant identification details (Delaware incorporation, Minneapolis headquarters at 3701 Wayzata Blvd, Suite 300, and IRS EIN 41-1801204). The filing contains no financial statements, revenue figures, or period-over-period operating data, so no performance comparison is possible.

  • · Filing is a 10-Q/A (amended quarterly report) rather than an original 10-Q
  • · Registrant incorporated in Delaware
  • · Principal executive offices: 3701 Wayzata Blvd, Suite 300, Minneapolis, Minnesota 55416
  • · IRS Employer Identification No.: 41-1801204
  • · Registrant telephone number: (612) 355-5100
  • · No financial results, revenue, or segment data disclosed in the provided content
TACTILE SYSTEMS TECHNOLOGY INC 10-Q/A neutral materiality 2/10

03-11-2026

Tactile Systems Technology filed a Form 10-Q/A (Amendment No. 1) solely to add previously omitted Rule 10b5-1 trading plan disclosures for director/Chairman William W. Burke and then-SVP Kristie Burns; no financial statements were changed or restated. Burke's plan (adopted August 12, 2025) covers sale of up to 30% of net shares from 16,078 vesting RSUs through May 29, 2026, while Burns' plan (adopted September 11, 2025) covers up to 9,139 shares through September 4, 2026. The amendment carries no revenue, earnings, or operational data, so there is no period-over-period financial performance to report.

  • · Amendment filed to correct an inadvertent omission of 10b5-1 plan disclosures from the original 10-Q filed November 3, 2025
  • · No changes made to the Company's financial statements in the original filing
  • · Burke's plan terminates on the earlier of May 29, 2026 or sale of all shares
  • · Burns' plan terminates on the earlier of September 4, 2026 or sale of all shares
  • · New Rule 13a-14(a)/15d-14(a) certifications (Exhibits 31.1 and 31.2) filed; Section 906 certifications omitted as no financial statements are included
  • · Amendment signed November 2, 2026 by CFO Elaine M. Birkemeyer
Crown Equity Holdings, Inc. 10-Q negative materiality 3/10

03-11-2026

Crown Equity Holdings filed its Q3 2026 10-Q reporting revenue of $102 for the three months ended September 30, 2026, down 63% from $279 a year earlier, while nine-month revenue fell 56% to $256 from $577. The quarterly net loss narrowed to $24,225 from $31,798, but the nine-month net loss widened to $93,715 from $59,380 as G&A expenses rose 17% and interest expense climbed 48%. Stockholders' deficit deepened to $407,778 from $314,062 at year-end 2025, with cash of just $1,137 and total liabilities of $417,495, raising going-concern-type liquidity concerns.

  • · Cash fell 50% to $1,137 from $2,272 at December 31, 2025, while total liabilities of $417,495 far exceed total assets of $9,717.
  • · Related-party notes payable rose to $232,443 from $169,712, and related-party accounts payable grew to $78,835 from $65,742.
  • · Nine-month 2026 net cash used in operating activities widened to $63,866 from $27,671, funded by $62,731 of related-party borrowings versus $18,905 a year earlier.
  • · No common stock was issued for cash in the first nine months of 2026, versus $8,000 (11,000 shares) in the prior-year period.
  • · Prior-year nine-month results included a $38,175 gain on debt conversion and a $19,579 loss on AP conversion; no comparable items in 2026.
  • · Weighted average diluted shares rose to 15,936,480 from 15,888,396 in the nine-month comparison.
  • · Net loss per share was $(0.00) in all periods presented.
Paymentus Holdings, Inc. 10-Q positive materiality 8/10

03-11-2026

Paymentus reported Q3 2026 revenue of $372.2M, up 19.8% YoY from $310.7M, with net income rising 54.9% to $27.5M and diluted EPS of $0.21 vs $0.14. Gross margin compressed to 25.2% from 24.1% a year earlier as cost of revenue grew 18.0%, while sales and marketing jumped 26.6% and R&D stayed essentially flat (+0.5%). Nine-month operating cash flow improved to $122.9M from $117.0M, but cash taxes paid more than doubled to $30.6M and contract liabilities declined sequentially.

  • · Gross margin was 25.2% in Q3 2026 vs 24.1% in Q3 2025, a modest 110 bps improvement despite cost of revenue rising 18.0%
  • · Nine-month revenue grew 26.0% to $1,091.4M from $866.0M, while nine-month net income rose 59.8% to $73.9M
  • · Cash paid for income taxes more than doubled to $30.6M in 9M 2026 from $11.1M, constraining operating cash flow growth to just 5.1%
  • · Contract liabilities fell to $5.8M at September 30, 2026 from $6.9M at December 31, 2025, suggesting softer deferred revenue
  • · Accounts receivable rose to $109.8M from $102.3M, a $7.7M use of cash vs a $14.8M source in the prior-year period
  • · Class B shares fell to 47.5M from 63.1M while Class A rose to 78.6M from 62.5M, reflecting ongoing share class conversion
  • · Capitalized internal-use software costs of $28.6M represented the bulk of investing outflows; net cash used in investing was $28.2M
  • · Stock-based compensation rose to $18.4M in 9M 2026 from $12.9M, and shares withheld for taxes increased to $9.4M from $7.2M
Match Group, Inc. 10-Q mixed materiality 8/10

03-11-2026

Match Group reported Q3 2026 revenue of $891.2M, down 2.5% YoY from $914.3M, while net income rose 8.5% to $174.4M and diluted EPS climbed 17.7% to $0.73, driven by a 10.1% reduction in total operating costs to $622.7M. Nine-month revenue was essentially flat at $2,608.3M (-0.04% YoY), but net income jumped 26.7% to $511.7M. However, selling and marketing (+9.4%) and product development (+14.1%) expenses rose in Q3, and cash fell to $726.2M from $1,027.8M at year-end 2025 while treasury stock purchases continued ($92.1M in Q3, $337.0M YTD).

  • · Q3 2026 cost of revenue fell 16.4% YoY to $206.5M from $247.0M
  • · Q3 2026 general and administrative expense fell 37.7% YoY to $92.2M from $148.0M
  • · Q3 2026 income tax provision rose to $50.4M from $32.9M, raising effective tax rate
  • · Interest expense increased to $41.5M in Q3 2026 from $37.0M in Q3 2025
  • · Other expense, net was $2.3M in Q3 2026 versus other income of $9.3M in Q3 2025
  • · Total shareholders' equity remained negative at $(139.5)M, though improved from $(253.4)M at year-end 2025
  • · Retained deficit narrowed to $(5,454.6)M from $(5,966.3)M at December 31, 2025
  • · Quarterly dividend raised to $0.20/share in Q3 2026 from $0.19/share in Q3 2025
  • · Stock-based compensation was $56.8M in Q3 2026, roughly flat YoY
  • · Goodwill stood at $2,340.4M and intangible assets at $157.0M at September 30, 2026
Emergent BioSolutions Inc. 10-Q negative materiality 8/10

03-11-2026

Emergent BioSolutions reported Q3 2026 total revenues of $110.0M, down 52.4% from $231.1M in Q3 2025, driven by a sharp decline in product and services sales (down 52.1% to $106.4M) and contracts and grants (down 60.4% to $3.6M). The company swung to a net loss of $32.7M (EPS -$0.64) from net income of $51.2M ($0.96 basic) a year earlier, while nine-month results were hit by a $191.3M impairment of long-lived assets, producing a net loss of $206.1M versus net income of $107.2M. However, operating cash flow improved to $122.4M for the nine months versus $92.9M, and interest expense fell 36.2% to $9.7M in Q3 as debt was reduced to $507.7M from $572.1M at year-end.

  • · SG&A rose 19.5% YoY to $46.5M in Q3 2026 from $38.9M, even as revenues fell, reflecting $6.1M of corporate restructuring costs in SG&A.
  • · Nine-month 2026 results included a $191.3M impairment of long-lived assets and a $14.3M loss on disposal of assets, versus none in the prior year.
  • · Diluted weighted average shares fell to 51.3M in Q3 2026 from 56.5M, and basic shares to 51.3M from 53.2M, reflecting treasury buybacks.
  • · Accumulated deficit widened to $365.9M at September 30, 2026 from $159.8M at December 31, 2025.
  • · Nine-month 2026 investing activities used $50.1M, including a $50.4M milestone payment from a prior asset transaction, versus $73.3M provided in the prior year.
  • · Financing activities used $104.5M in nine months 2026, including $150.0M repayment of the prior term loan facility offset by $145.5M of new debt proceeds and $68.1M of debt repurchases.
  • · Inventories declined to $280.9M from $343.4M at year-end, contributing $62.6M of operating cash inflow.
  • · Deferred revenue rose to $14.3M from $5.0M at December 31, 2025.
  • · Nine-month 2026 income tax provision was $16.8M versus $26.3M in the prior year.
REALTY INCOME CORP 10-Q mixed materiality 8/10

03-11-2026

Realty Income reported Q3 2026 total revenue of $1.62B, up 10.3% YoY from $1.47B, and nine-month revenue of $4.72B, up 10.7% YoY, driven by rental growth (+7.0% QoQ-equivalent YoY) and a sharp jump in interest/dividend income on loans and preferred equity (+105.6% YoY to $105.0M). Net income available to common stockholders rose 27.9% YoY to $403.9M and diluted EPS increased to $0.43 from $0.35. However, total expenses grew 8.2% YoY, interest expense rose 13.3% to $333.6M, and impairment provisions jumped 48.1% to $111.6M, while nine-month general and administrative costs rose 15.1% and credit loss provisions more than doubled to $60.6M.

  • · Nine-month 2026 general and administrative expense rose 15.1% YoY to $170.8M from $148.4M
  • · Nine-month 2026 credit loss provisions more than doubled to $60.6M from $31.9M
  • · Q3 2026 impairment provisions increased 48.1% YoY to $111.6M from $75.4M
  • · Nine-month 2026 net cash used in investing activities was $7.00B versus $3.55B in 2025, reflecting heavier acquisition activity
  • · Investment in real estate for nine months 2026 was $5.58B versus $3.09B in 2025
  • · Nine-month 2026 cash distributions to common stockholders were $2.28B versus $2.18B in 2025
  • · Total assets grew to $77.95B at September 30, 2026 from $72.80B at December 31, 2025
  • · Notes payable, net increased to $26.45B from $25.03B at year-end 2025
  • · Nine-month 2026 net cash provided by operating activities was $2.95B versus $2.79B in 2025
  • · Q3 2026 gain on sales of real estate was $113.9M versus $49.1M in Q3 2025

Get daily alerts with 12 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 42 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Pre-Market SEC Filings Roundup

🇺🇸 More from United States

View all →